Skip to main content Deutsch



Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy. J Clin Virol.

Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathy. J Autoimmun


Amino acids fuel fibroblast-like synoviocyte activation and arthritis by regulating chemokine expression and leukocyte migration. Arthritis Rheumatol

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis.

Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis. Ann Rheum Dis
/!\ Watch our dedicated video on this link.

Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach. Front Immunol.

Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases. J Autoimmun.

Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clin Microbiol Infect.

[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)]. Z Rheumatol.

Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study. Clin Infect Dis.



Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency. Front Immunol.

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis.

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun.

National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wien Klin Wochenschr.

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann Rheum Dis.

Neuropsychiatric Systemic Lupus Erythematosus: A Remaining Challenge. Curr Pharm Des.

TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. Rheumatology (Oxford).

Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis.

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis.

Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology (Oxford).



Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe : Ein Positionspapier der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und des Ärzteverbands Deutscher Allergologen (AeDA). Allergo J.

Preclinical models of arthritis for studying immunotherapy and immune tolerance. Ann Rheum Dis.

Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. Eur J Immunol.

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis.

Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper. Allergo J Int.

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis.

Deficiency of Cathelicidin-related Antimicrobial Peptide Promotes Skin Papillomatosis in Mus musculus Papillomavirus 1-infected Mice. Acta Derm Venereol.

Mus musculus papillomavirus 1 is a key driver of skin cancer development upon immunosuppression. Am J Transplant.



Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. J Autoimmun.

Treg cells in health and autoimmune diseases: New insights from single cell analysis. J Autoimmun.

Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient-Addendum to the Genotype-Phenotype Puzzle. J Clin Immunol.



IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs. Exp Mol Med.

MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. Front Immunol.

Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol.



CCR6 controls autoimmune but not innate immunity-driven experimental arthritis. J Cell Mol Med.

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol.

Non-classical monocytes as mediators of tissue destruction in arthritis. Ann Rheum Dis.

How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol.

A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis. J Autoimmun.



MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. J Autoimmun.

Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. Elife.

Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatology (Oxford).

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol.



Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Arthritis Res Ther.

EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion. Sci Rep.

Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. Immunity.



Transcriptional and epigenetic networks of helper T and innate lymphoid cells. Immunol Rev.

Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog.

Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes. Curr Top Microbiol Immunol.

CD4⁺CD25⁻Foxp3⁺ T cells: a marker for lupus nephritis? Arthritis Res Ther.

Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PLoS One.



BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature.

A dynamic real time in vivo and static ex vivo analysis of granulomonocytic cell migration in the collagen-induced arthritis model. PLoS One.

Regulatory T cells form stable and long-lasting cell cluster with myeloid dendritic cells (DC). Int Immunol.

Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritis. Wien Klin Wochenschr.



Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum.

Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun.

Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol.

Access site management after peripheral percutaneous transluminal procedures: Neptune pad compared with conventional manual compression. Radiology.

Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol.